Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer
A Cost-Effectiveness Analysis
Datos Bibliográficos
| ID | 22074412 |
|---|---|
| Autores | Xiaoyan Liu (0000-0002-8276-907X, Macau University of Science and Technology), Yitian Lang (0000-0003-3926-5412, Shanghai Jiao Tong University), Yahui Liao (Shanghai Jiao Tong University), Yi Zhun Zhu (0000-0001-7700-8041, Macau University of Science and Technology, autor de correspondencia), Yizhun Zhu |
| Año | 2021 |
| Volumen | 9 |
| Páginas | 756899-756899 |
| Fecha de publicación | 2021-10-29 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | Frontiers in Public Health (JOURNAL) |
| Identificadores de la revista | ISSN: 2296-2565 • E-ISSN: 2296-2565 |
| Editorial | Frontiers Media SA (PUBLISHER • CH) |
| DOI | 10.3389/fpubh.2021.756899 |
| PMID | 34778188 |
| OpenAlex | W3209650748 |
| Idioma | EN |
| Citas recibidas | 1 |
| Referencias citadas | 29 |
Purpose: The IMpassion130 trial demonstrated the efficacy of adding atezolizumab to paclitaxel for advanced or metastatic triple-negative breast cancer (TNBC). The current study evaluated the cost-effectiveness of adding atezolizumab to nab-paclitaxel for TNBC from the perspective of Chinese health sector. Methods: A partitioned survival model was implemented for patients with TNBC. The survival data were derived from IMpassion130 trial. Direct costs and utility values were collected from the Chinese Drug Bidding Database and published literatures. The primary analysis outcomes were quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Sensitivity analyses were performed to observe model stability. Results: In the base-case analysis, the ICER of atezolizumab plus nab-paclitaxel vs. nab-paclitaxel is respectively, $176,056/QALY, $118,146/QALY, and $323,077/QALY in the ITT, PD-L1(+) and PD-L1(–) group. Conclusion: Adding atezolizumab to nab-paclitaxel could improve survival time significantly in the PD-L1-positive group, but it is not a cost-effective strategy compared to nab-paclitaxel monotherapy for Chinese patients with advanced or metastatic triple-negative breast cancer in the current economic context of China
Atezolizumab · Breast cancer · Cancer · Chemotherapy · Eribulin · Immunotherapy · Metastatic breast cancer · Paclitaxel · Pembrolizumab · Triple-negative breast cancer · Cancer Immunotherapy and Biomarkers · Colorectal Cancer Treatments and Studies · HER2/EGFR in Cancer Research · Medicine · Internal Medicine · Oncology
| Obras citantes distintas | 1 |
|---|---|
| Citas por año | 0,5 |
| Intervalo de citas | 2024 - 2024 (1) |
| Velocidad de citación | recent |
| Altamente citado | No |
| Tipos de cita | Neutras: 1 |